Faricimab - Latest Advances

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report.

Journal: The American journal of case reports

Published: November 25, 2025

Early anatomical outcomes of faricimab vs. aflibercept 2 mg in treatment-naïve neovascular AMD and PCV: A head-to-head comparative study in Taiwan.

Journal: Journal of the Chinese Medical Association : JCMA

Published: November 24, 2025

Environmental and Financial Cost Savings With Low-Consumption Intravitreal Injection Techniques.

Journal: Journal of vitreoretinal diseases

Published: November 17, 2025

One-year Real-world Outcomes and Durability With Faricimab in Patients With Diabetic Macular Edema.

Journal: Ophthalmic surgery, lasers & imaging retina

Published: November 04, 2025

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice.

Journal: International journal of retina and vitreous

Published: November 02, 2025

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid.

Journal: European journal of ophthalmology

Published: October 21, 2025

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Journal: BMJ open

Published: October 08, 2025

The Implementation of Faricimab in East Lancashire NHS Trust: Highlighting the Real-World Efficacy and Safety in Patients With Neovascular Age-Related Macular Degeneration.

Journal: Cureus

Published: September 29, 2025

Erratum in: Comments on "Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema".

Journal: Investigative ophthalmology & visual science

Published: September 29, 2025

Computational modeling of anti-VEGFA drug interactions with VEGF-A: Insights into therapeutic strategies for neovascular AMD.

Journal: Computational biology and chemistry

Published: September 25, 2025

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries.

Journal: Ophthalmology. Retina

Published: September 21, 2025

Intravitreal Faricimab for the Management of Bilateral Macular Neovascularization Secondary to Macular Telangiectasia Type 2.

Journal: Cureus

Published: September 18, 2025

Filters

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report.

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report.

Early anatomical outcomes of faricimab vs. aflibercept 2 mg in treatment-naïve neovascular AMD and PCV: A head-to-head comparative study in Taiwan.

Early anatomical outcomes of faricimab vs. aflibercept 2 mg in treatment-naïve neovascular AMD and PCV: A head-to-head comparative study in Taiwan.

Environmental and Financial Cost Savings With Low-Consumption Intravitreal Injection Techniques.

Environmental and Financial Cost Savings With Low-Consumption Intravitreal Injection Techniques.

One-year Real-world Outcomes and Durability With Faricimab in Patients With Diabetic Macular Edema.

One-year Real-world Outcomes and Durability With Faricimab in Patients With Diabetic Macular Edema.

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice.

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice.

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid.

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid.

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

The Implementation of Faricimab in East Lancashire NHS Trust: Highlighting the Real-World Efficacy and Safety in Patients With Neovascular Age-Related Macular Degeneration.

The Implementation of Faricimab in East Lancashire NHS Trust: Highlighting the Real-World Efficacy and Safety in Patients With Neovascular Age-Related Macular Degeneration.

Erratum in: Comments on "Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema".

Erratum in: Comments on "Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema".

Computational modeling of anti-VEGFA drug interactions with VEGF-A: Insights into therapeutic strategies for neovascular AMD.

Computational modeling of anti-VEGFA drug interactions with VEGF-A: Insights into therapeutic strategies for neovascular AMD.

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries.

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries.

Intravitreal Faricimab for the Management of Bilateral Macular Neovascularization Secondary to Macular Telangiectasia Type 2.

Intravitreal Faricimab for the Management of Bilateral Macular Neovascularization Secondary to Macular Telangiectasia Type 2.